Author/Editor		Vera-Badillo, Francisco; Templeton, Arnoud J.; Gouveia, Paulo de; Diaz-Padilla, Ivan; Bedard, Philippe L.; Al-Mubarak, Mustafa; Šeruga, Boštjan; Tannock, Ian; Ocaña, Alberto; Amir, Eitan
Title		Androgen receptor expression and outcomes in early breast cancer
Type		članek
Vol. and No.		Letnik 106, št. 1
Publication year		2014
Volume		str. 1-11
ISSN		0027-8874 - Journal of the National Cancer Institute
Language		eng
Abstract		Background: The androgen receptor (AR) is expressed frequently in breast cancer, but its prognostic significance is unclear. Preclinical data suggest that expression of AR may modify clinical outcomes in early breast cancer with improved prognosis in estrogen receptor (ER)-positive disease and poorer prognosis in ER-negative disease. Methods: A systematic review of electronic databases was conducted to identify studies published between 1946 and July 2012 and to explore the association between AR expression and overall survival (OS) and disease-free survival (DFS) in women diagnosed with early breast cancer. The odds ratios (OR) for OS and DFS at 3 and 5 years were calculated and then weighted and pooled in a meta-analysis with Mantel-Haenszel random-effect modeling. All statistical tests were two-sided. Results: Nineteen studies with a total of 7693 women were included. AR expression was documented in 60.5% of patients. ER-positive tumors were more likely to express AR- than ER-negative tumors (74.8% vs 31.8%, (2) P < .001). Compared with tumors without AR expression, those expressing AR were associated with improved OS at both 3 and 5 years (OR = 0.47, 95% confidence interval [CI] = 0.39 to 0.58, P < .001; and OR = 0.40, 95% CI = 0.29 to 0.56, P < .001). The absolute differences in the probability of OS at 3 and 5 years were 6.7% (95% CI = 3.5% to 9.8%) and 13.5% (95% CI = 7.5% to 19.6%), respectively. Results for 3- and 5-year DFS were similar. Coexpression of the ER did not influence OS at 3 or at 5 years. CONCLUSIONS: Expression of AR in women with breast cancer is associated with better OS and DFS irrespective of coexpression of ER.
Keywords		rak dojke androgeni receptorji klinične študije zgodnji rak dojke